Sanofi (SNYNF) EPS (Weighted Average and Diluted) (2009 - 2025)

Sanofi has disclosed EPS (Weighted Average and Diluted) across 17 years of filings, most recently posting -$2.34 for Q4 2025.

• EPS (Weighted Average and Diluted) for Q4 2025 came in at -$2.34, down 1551.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.34 (down 1551.33% YoY), and the FY2025 annual result was $7.41, up 56.64% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$2.34 for Q4 2025 at Sanofi, down from $1132.6 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1132.6 in Q2 2025 to a low of -$2.34 in Q4 2025.
• The 5-year median for EPS (Weighted Average and Diluted) is $16.41 (2024), against an average of $354.98.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 4002.66% in 2025, while the deepest fall reached 1551.33% in 2025.
• Sanofi's EPS (Weighted Average and Diluted) stood at $0.2 in 2021, then jumped by 2484.45% to $5.21 in 2022, then plunged by 106.71% to -$0.35 in 2023, then soared by 59.44% to -$0.14 in 2024, then slumped by 1551.33% to -$2.34 in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at -$2.34 (Q4 2025), $1132.6 (Q2 2025), and -$0.14 (Q4 2024), per Business Quant data.